Six principles for reading Japanese compounders.

The P/E ratio makes Japanese stocks look more expensive than they actually are, because it does not see the cash sitting on the balance sheet. Conservative Japanese mid-cap companies often carry net cash worth 20–40% of their market value — and the most interesting compounders tend to sit in that part of the market. A multiple applied to the share price alone says nothing about how much of that price is the operating business, and how much is a savings account the shareholder owns indirectly through the company's balance sheet.

Enterprise value — market value plus debt, less cash — takes that savings account out of the calculation. Enterprise value divided by EBIT is what the operating business is actually valued at. Reported earnings depend on tax rates, one-time items, foreign-exchange translation noise, and equity-method accounting that differs from company to company. EBIT looks at the operating engine itself. EBITDA flatters capital-intensive businesses by hiding depreciation. EV/EBIT is the simplest honest read of what the market is paying for operating profit, and it is the measure we display on every Compounder Profile.

The pattern across the small-cap portfolio managers we have spoken with is consistent: cheap comes before everything else. The screen has a single anchor — companies trading below 10x EV/EBIT, or close to it — and the rest of the analysis is run on the companies that pass that filter. Paying any price for quality is the framework of the largest endowments and a few concentrated long-duration funds. For most small-cap mandates, valuation is the entry filter and quality is what gets applied within the resulting universe. Starting valuation is what gives the position room to absorb a mistake.

Within that cheap universe, the second filter is capital efficiency — measured as Return on Capital Employed (ROCE), defined as EBIT divided by total assets less current liabilities. We use ROCE rather than Return on Equity because leverage distorts ROE, and rather than Return on Invested Capital because the invested-capital denominator turns negative for cash-rich asset-light businesses — which Japanese compounders often are. ROCE works across the structures we actually encounter. The threshold is 15% sustained over time, with a three-year trend that is at least flat.

The Japanese deep-value story — buying companies that trade below the book value of their assets — has already had an extensive three-year run. The obvious candidates have largely been repriced as investors followed the Tokyo Stock Exchange's PBR-reform program into the most striking cases. What remains in the low-P/B part of the market is increasingly a group of businesses that are priced about right — capital-intensive, low-returning, cyclical, and structurally unable to grow equity at meaningful rates.

The institutional view is different. A business compounding equity at 20% a year roughly doubles book value over five years, before any change in the multiple. A business compounding at 5% barely moves it — and the value to a patient shareholder there is whatever the multiple eventually does, not what the business does. The first situation is the one a small-cap portfolio manager wants on the book. The second is a bet that the multiple will rise someday, with no compounding in the meantime.

The practical consequence is exclusionary: capital-intensive low-returning businesses are filtered out of the compounder universe even when their price-to-book ratio looks attractive. The universe tilts instead toward asset-light, owner-led, niche-dominant businesses where reinvestment translates directly into growth of book value, and where the absence of heavy physical-asset spending keeps ROCE high through cycles. That tilt is a deliberate consequence of taking the long arc seriously.

The compounders worth holding for ten years are usually not the ones with obvious global counterparts. They are the ones whose structural advantage is specifically Japanese — a niche the company dominates, a regulatory or geographic monopoly, or a brand that an owner-founder has spent decades building. And precisely because that kind of moat does not have an obvious global comparable, it does not appear on most foreign screens.

Buffett's understandability test — invest in what you understand — has an unintended consequence when a foreign investor applies it to Japan. It filters toward companies that look like things the investor already knows: a semiconductor equipment maker, a global pharmaceutical company, a megabank — readable, easy to screen, and competing in a global market against global comparables. The most distinctive Japanese compounders fail that test on first glance — not because they are unintelligible, but because they have no obvious template.

The general pattern: the moat does not have to be technological or globally famous. It only has to be structural, durable, and rooted in local conditions. What unifies the most interesting cases is insulation from global commodity-style competition — the same kind of price-driven competition that erodes returns elsewhere is the thing these businesses have structurally avoided.

This principle shapes both the Compounder Profile's CONTENTION section, where moat durability is consistently among the three debates surfaced, and the editorial selection of which companies receive a Profile at all. A company without a recognizable moat does not enter coverage, regardless of how it looks on a valuation screen.

The take-private channel in Japan has changed from incidental to structural over the past several years. Activists arriving with explicit privatization theses, domestic and global private-equity buyers with capital specifically earmarked for Japan, and management buyout transactions have all become routine ways the market puts a price on small- and mid-cap companies. A recent wave of high-profile transactions has set a real benchmark range.

The practical consequence for valuation work is that a portfolio manager's estimate of intrinsic value now has two anchors. The first is the conventional public-market exit, modeled at peer-median multiples. The second is the private-buyer bid — what a strategic acquirer or a private-equity buyer would pay for the business if it were taken private. The two anchors diverge most for compounders, because private buyers can pay for the strategic optionality that the public market does not price.

Recent transaction multiples have tended to cluster in the 7–10x EV/EBIT range for stable, cash-generative mid-cap companies, with premiums over the public quote routinely reaching 30–50%. Where a compounder trades below 8x EV/EBIT in the public market, the private-buyer bid is essentially the floor: the deal is mechanically attractive to a private-equity buyer with a normal cost of capital and operating discipline. Where the company trades above 12x, the public-market multiple is doing the work, and the private-buyer anchor recedes.

The VALUATION section of every Compounder Profile is anchored in scenarios, not in a price target. Where the private-buyer bid is mechanically relevant — usually in the bear and base scenarios — it appears as one of the floor levels. This is not a take-private forecast. It is the second anchor of intrinsic value, surfaced where it materially constrains the downside.